Search Site | Index

About Lymphoma | Advocacy | Art | CAM | Clinical trials 
Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms |
Tests | Treatments | Types of Lymphoma | How to Help

Find Clinical Trial

 by Agent

by Type of Lymphoma & Treatment Status  

Trials of Interest

New trials since October 2018

Phase I since 2017  | Phase III since 2008

Guidelines at Diagnosis | About Clinical Trials

evidence-based support and information


About LymphomaImmune suppression

Last update: 03/13/2014

Introduction | Resources and Research News

Cells of the Immune SystemImmune suppression is a known risk factor for developing lymphomas based on the higher incidence of lymphoma in persons receiving drugs to prevent rejection of transplanted organs from donors.

It's also a known consequence of disease progression. The tumor cells seem to make substances that dampen or distort immune function, or the malignant cells may accumulate in organs involved in immune cell development or maturation, such as the bone marrow, spleen, lymph nodes. 

Immune suppression is also a common side effect of standard treatments, an effect with is generally reversible with time.

See also The Immune System


[J Nephrol. 1997
Incidence and consequences of post-transplant lymphoproliferative disorders
National Cancer Institute
The Immune System and Cancer -
Risk factors for Lymphoma PAL
Lymphoma Immunization Guide  PAL



In the News

{beta}2-microglobulin -[associated with  NHL progression] as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood. 2003 Jan 16  PMID: 12531797  PubMed
Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL). Leuk Lymphoma. 2002 Jun;43(6):1313-21. PMID: 12153001 PubMed
The Prevalence of Blastocystis Hominis in Immunosuppressed Patients

Treatment-related immune suppression

Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 2002 Oct;119(1):125-7. PMID: 12358915 PubMed
Frequency and type of serious infections in Fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002 Apr 1;94(7):2033-9. PMID: 11932906 PubMed
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002 May;26(5):630-6. PMID: 11979093 PubMed

related Immune-dysfunction

B-cell lymphomas involving the skin associated with hepatitis C virus infection. Int J Dermatol. 2002 Sep;41(9):577-82. PMID: 12358827 - PubMed
Disclaimer:  The information on is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns, you should always consult your doctor. 
Copyright 2004,  All Rights Reserved.